Qureight’s presence at the upcoming American Thoracic Society (ATS) 2025 International Conference, taking place from 18–21 May in San Francisco, highlights both the progression and power of the company’s AI-driven image analytics and data science in advancing the treatment of fibrotic lung diseases.
Over the course of the event, Qureight will take part in eight sessions, including three mini symposium presentations and five poster presentations, delivered in collaboration with partners including Avalyn Pharma, Endeavor BioMedicines, AstraZeneca and the Australian IPF Registry.
Dr Simon Walsh, Chief Scientific Officer at Qureight, said: "We’re thrilled to have such a strong presence at ATS 2025 – it’s a real milestone that reflects the progress we've made in applying deep learning and imaging science to fibrotic lung disease. Sharing our work across eight sessions shows just how far the field has come, and we're excited to contribute to the global conversation shaping the future of respiratory medicine."
Qureight’s contributions span a range of topics – from deep learning-based CT analysis models and real-world data integration to novel biomarker identification, outcome prediction and the development of synthetic study arms. During these sessions Qureight will present findings from multiple international clinical studies and highlight how Qureight’s platform is enabling a new era of trial design and disease monitoring in idiopathic pulmonary fibrosis (IPF) and related lung diseases.
The team will be sharing their expert perspectives on advanced imaging analytics, biomarker development and the future of AI-enabled clinical trials in respiratory medicine.
Confirmed activity at the conference
1. Thematic Poster – Monte Carlo External Control Arm Generation Utilising Real-world Patient Data and Deep Learning-based Quantitative CT Metrics Demonstrates Treatment Effect in the Atlas IPF Trial (co-presenting with Avalyn Pharma)
Date: 18th May 2025, 11.30-13.15
Session: A57, Late Breaking Abstracts in Clinical Problems
Location: Poster Board 1009
2. Mini Symposium – Deep Learning-based Quantitative CT and Proteomics for Predicting Outcomes in Idiopathic Pulmonary Fibrosis
Date: 18th May 2025, 15.15-15.27
Presenter: Simon Walsh
Session: A95, New and Exciting Biomarkers in ILD (Mini Symposium)
3. Poster Discussion – Combined Deep Learning Algorithms Demonstrate That Both Computed Tomography Phenotype and Anatomical Biomarkers Are Predictive of Prognosis and Progression in Idiopathic Pulmonary Fibrosis
Date: 20th May 2025, 09.15-11.15
Session: C23, On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD
Location: Poster Board 607
4. Poster Discussion – Deep Learning Quantitative Computed Tomography Analysis in the Australian Idiopathic Pulmonary Fibrosis Registry
Date: 20th May 2025, 09.15-11.15
Session: C23, On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD
Location: Poster Board 609
5. Poster Discussion – Deep Learning-based Disease Severity Biomarkers on CT; Posthoc Analysis in a Phase 2a Placebo-controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (co-presenting with Endeavor BioMedicines)
Date: 20th May 2025, 09.15-11.15
Session: C23, On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD (Poster Discussion)
Location: Poster Board 610
6. Poster Discussion – Dose-Dependent Change of Inhaled Pirfenidone Seen in Lung Volume and Fibrosis Quantification in Patients With IPF: A Deep Learning Image-Based Analysis of Data From the ATLAS Phase 1b Trial (co-presenting with Avalyn Pharma)
Date: 20th May 2025, 09.15-11.15
Session: C23, On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD (Poster Discussion)
Location: Poster Board 601
7. Mini Symposium – Deep Learning-Based Quantitative CT and CT Phenotype Classification Independently Predict Mortality in Idiopathic Pulmonary Fibrosis, a Prospective Observational Cohort Study
Date: 21st May 2025, 12.24-12.36
Presenter: Simon Walsh
Session: D91, Imaging-Based Advances in Fibrotic ILD
8. Mini Symposium – Deep Learning-Based Short-Term Disease Progression Evaluation Supersedes Automated Baseline CT Phenotype in Predicting Outcomes in Idiopathic Pulmonary Fibrosis
Date: 21st May 2025, 12.36-12.48
Presenter: Simon Walsh
Session: D91, Imaging-Based Advances in Fibrotic ILD